Stamford biopharmaceutical company Cara Therapeutics Inc. has named Christopher Posner as its next president and CEO, effective Nov. 9.
Posner, who is a member of the company”™s board of directors, was previously president and CEO of Leo Pharma Inc., the U.S. affiliate of Denmark”™s LEO Pharma A/S, a pharmaceutical company focused on medical dermatology products.
Earlier in his career, he held senior management positions at R-Pharma-US LLC, Bristol-Myers Squibb Co., Pfizer Inc., Wyeth Pharmaceuticals Inc. and Endo Pharmaceuticals plc.
Posner succeeds Derek Chalmers, who will transition to a senior adviser role. Chalmers co-founded the company and had served as its leader since 2004.
